The Filing Desk

Kura Oncology vs Rockwell Medical

Kura Oncology KURA · Rockwell Medical RMTI · Pharmaceuticals

Rockwell Medical reported revenue of $69 million in fiscal 2025, about the same as Kura Oncology's $68 million in fiscal 2025. Kura Oncology's revenue grew 25.2% in its latest year, and Rockwell Medical's fell 31.8%. Kura Oncology had an operating margin of -449.9%, against -6.8% at Rockwell Medical. Free cash flow was −$71 million at Kura Oncology and −$1 million at Rockwell Medical.

Side by side

Kura OncologyRockwell Medical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$68M$69M
Revenue growth25.2%−31.8%
Revenue growth a year, last 5 years—2.2%
Gross margin—16.9%
Operating margin−449.9%−6.8%
Net margin−412.9%−7.7%
Free cash flow−$71M−$1M
Free cash flow margin−104.8%−1.7%
Return on capital—−17.4%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.8%15.8%
Last close$7.35$6.26
P/E at the last close——
Insider trades, last 12 monthsbought $3.9 million, sold $4.0 millionsold $3,153
Piotroski F-score3 of 83 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kura OncologyRockwell Medical
Operating margin
Percent of revenue
Kura OncologyRockwell Medical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kura OncologyRockwell Medical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kura Oncology and Rockwell Medical pages.